2017
TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma
Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma. Cancer 2017, 123: 1778-1790. PMID: 28295222, PMCID: PMC5419871, DOI: 10.1002/cncr.30570.Peer-Reviewed Original ResearchConceptsHPV-positive HNSCCNeck squamous cell carcinomaDe-escalation therapyHPV-positive HNSCCsMechanisms of HPVRecurrent metastatic diseaseBetter overall survivalSquamous cell carcinomaNuclear factor-κB signalingFactor-κB signalingNew therapeutic strategiesNuclear factor κBHPV vaccineCancer Genome AtlasCurative optionHPV statusMetastatic diseaseOverall survivalCervical cancerPatient survivalSmoking characteristicsCell carcinomaHuman papillomavirusLifelong morbidityClinical trials
2011
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 2011, 14: 260-279. PMID: 21920801, PMCID: PMC3195944, DOI: 10.1016/j.drup.2011.08.002.Peer-Reviewed Original ResearchConceptsEGFR/ErbB inhibitorsControl of EGFRPost-translational modificationsErbB family proteinsNew agentsSTAT proteinsFamily proteinsTransmembrane receptorsSquamous cell carcinomaLigand availabilityEffective therapeutic combinationsNew therapeutic strategiesPI3KErbB inhibitorsClinical benefitCell carcinomaMajor research goalNeck cancerProteinCause of resistanceValuable therapyTherapeutic combinationsTherapeutic strategiesTherapeutic inhibitionClinical development